Lercaprel

Enalapril maleate, the active ingredient in Lercaprel, is an ACE inhibitor presented as an oral tablet for hypertension treatment in adults. It works together with lercanidipine hydrochloride, a calcium‑channel blocker, to provide dual blood‑pressure control.

GNH USA supplies Lercaprel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercaprel is indicated for the management of hypertension, a condition characterized by elevated arterial pressure. - Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Isolated systolic hypertension: provides effective control of high systolic readings. - Hypertension uncontrolled by monotherapy: offers combined ACE‑inhibitor and calcium‑channel blockade for patients needing dual therapy.

Lercaprel may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Cough: dry, persistent throat irritation. - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially after standing. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing faintness. - Hyperkalemia: elevated blood potassium levels. - Renal impairment: worsening kidney function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Myocardial infarction: rare occurrence of heart attack.

Before prescribing Lercaprel, clinicians should evaluate patient history and comorbid conditions. - Renal function: assess creatinine clearance and adjust therapy if needed. - Hepatic disease: monitor liver enzymes and avoid use in severe impairment. - Electrolyte balance: check potassium levels, especially if combined with potassium‑sparing agents. - Pregnancy: avoid use unless clearly needed; discuss risks with obstetric specialist. - Elderly patients: start at lower dose and monitor for hypotension. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Lercaprel can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Aliskiren in diabetic patients: increased renal adverse events. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely):\n- Other antihypertensives (beta‑blockers, diuretics): may cause additive hypotension. - Lithium: risk of lithium toxicity due to reduced clearance. - CYP3A4 inhibitors (e.g., ketoconazole): may increase lercanidipine plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce lercanidipine efficacy.